A biomarker-driven approach to targeting polyamine depletion in triple negative breast cancer

Background

Triple negative breast cancer (TNBC) is the most aggressive and heterogenous breast cancer subtype. Polyamines are essential for TNBC growth and proliferation; however, therapeutic strategies targeting polyamine metabolism have shown limited efficacy in TNBC. In this study, we demonstrate a biomarker-driven approach to treating TNBC through polyamine depletion. As the rate limiting catabolic enzyme in the polyamine pathway, spermidine/spermine N1-acetlytransferase (SAT1) reduces polyamines and generates the metabolite, diacetylspermine.